Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis—A randomized controlled study
Allergy · 2023-07 · 78 (7) · 1964-1979
DOI: 10.1111/all.15690 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 21.03.2023. Verfasst von Lise Gether und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Insulin Resistance, Diabetes Mellitus, Type 2, Dermatologic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Aage Bang's Foundation, LEO Pharma A/S, The Innovation Fund Denmark.
Abstract (Originalsprache)
Introduction
Topical corticosteroids (TCS), used to treat atopic dermatitis (AD), have been associated with type 2 diabetes and osteoporosis in epidemiological studies, possibly explained by systemic absorption.
Objectives
We examined whether intensive daily whole‐body TCS treatment over 2 weeks followed by twice weekly application for 4 weeks could elicit insulin resistance and increase bone resorption in adults with AD.
Methods
A randomized parallel‐group double‐blind double‐dummy non‐corticosteroid‐based active comparator study design was completed in Copenhagen, Denmark. Thirty‐six non‐obese, non‐diabetic adults with moderate‐to‐severe AD were randomized to whole‐body treatment with betamethasone 17‐valerate 0.1% plus a vehicle once daily or tacrolimus 0.1% twice daily after washout. Insulin sensitivity assessed by the hyperinsulinemic‐euglycemic clamp combined with tracer infusions and biomarkers of bone formation (P1NP) and resorption (CTX) were evaluated at baseline, after 2 weeks of daily treatment and after further 4 weeks of twice‐weekly maintenance treatment.
Results
AD severity improved with both treatments and systemic inflammation was reduced. After 2 weeks, we observed similar increase in peripheral insulin sensitivity with use of betamethasone ( n = 18) and tacrolimus ( n = 18). Bone resorption biomarker, CTX, was unchanged, while bone formation marker, P1NP, decreased after betamethasone treatment after both 2 and 6 weeks but remained unchanged in the tacrolimus arm.
Conclusions
Whole‐body treatment with TCS leads to systemic exposure but appears not to compromise glucose metabolism during short‐term use, which may be a result of reduced systemic inflammatory activity. The negative impact on bone formation could be regarded an adverse effect of TCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
- Department of Dermatology and Allergy, Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
- LEO Pharma A/S, Ballerup, Denmark.
- Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
- Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
- Department of Chemistry and Biochemistry, Laboratory for Analytical Chemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.
ORCID-Profile: Lise Gether, Heidi Storgaard, Sanja Kezic, Ivone Jakasa, Bolette Hartmann, Kirsa Skov-Jeppesen, Jens J Holst, Anders J Pedersen, Julie Forman, Gerrit van Hall, Ole E Sørensen, Lone Skov, Mads A Røpke, Filip K Knop, Jacob Pontoppidan Thyssen
Förderung
- Aage Bang's Foundation
- LEO Pharma A/S
- The Innovation Fund Denmark
- Kongelig Hofbuntmager Aage Bangs Fond
Zitieren
APA
Gether, L., Storgaard, H., Kezic, S., Jakasa, I., Hartmann, B., Skov-Jeppesen, K., Holst, J. J., Pedersen, A. J., Forman, J., van Hall, G., Sørensen, O. E., Skov, L., Røpke, M. A., Knop, F. K., & Thyssen, J. P. (2023). Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis—A randomized controlled study. Allergy, 78(7), 1964-1979. https://doi.org/10.1111/all.15690
Vancouver
Gether L, Storgaard H, Kezic S, Jakasa I, Hartmann B, Skov-Jeppesen K, et al. Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis—A randomized controlled study. Allergy. 2023;78(7):1964-1979. doi:10.1111/all.15690
BibTeX
@article{Gether2023,
author = {Gether, Lise and Storgaard, Heidi and Kezic, Sanja and Jakasa, Ivone and Hartmann, Bolette and Skov-Jeppesen, Kirsa and Holst, Jens J and Pedersen, Anders J and Forman, Julie and van Hall, Gerrit and Sørensen, Ole E and Skov, Lone and Røpke, Mads A and Knop, Filip K and Thyssen, Jacob Pontoppidan},
title = {Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis—A randomized controlled study},
journal = {Allergy},
year = {2023},
volume = {78},
number = {7},
pages = {1964--1979},
doi = {10.1111/all.15690}
}
EUVIMED